The first CAR T product for relapsed MM, idecabtagene vicleucel (ide-cel), was approved in 2021 for patients who have received 4 or more prior lines including an IMiD, a PI, and a CD38-directed MoAb. This evidence concerns the gene CD38 and Miyoshi myopathy.